Regeneron Pharmaceuticals, Inc. (REGN)
Will Regeneron (REGN) Beat Estimates Again in Its Next Earnings Report?
Regeneron (REGN) has an impressive earnings surprise history and currently possesses the right combination of the two key ingredients for a likely beat in its next quarterly report.
Why Regeneron (REGN) is a Top Value Stock for the Long-Term
Whether you're a value, growth, or momentum investor, finding strong stocks becomes easier with the Zacks Style Scores, a top feature of the Zacks Premium research service.
Regeneron Pharmaceuticals, Inc. (REGN) Discusses Expanded Collaboration on Next-Generation Long-Acting Immunology Antibodies Transcript
Regeneron Pharmaceuticals, Inc. (REGN) Discusses Expanded Collaboration on Next-Generation Long-Acting Immunology Antibodies Transcript
Regeneron drug halves muscle loss in combination with Novo's semaglutide in trial
An experimental weight-loss drug being developed by Regeneron used in combination with Novo Nordisk's semaglutide reduced the loss of muscle mass by 50% compared with the loss seen with semaglutide alone in a study of patients with obesity, according to data being presented at a medical meeting.
Regeneron Pharmaceuticals, Inc. (REGN) Presents at Bernstein Insights: Healthcare Leaders and Disruptors - 3rd Annual Healthcare Forum Transcript
Regeneron Pharmaceuticals, Inc. (REGN) Presents at Bernstein Insights: Healthcare Leaders and Disruptors - 3rd Annual Healthcare Forum Transcript
Regeneron Highlights EYLEA HD Momentum, Dupixent Growth and Pipeline Catalysts
Regeneron Pharmaceuticals NASDAQ: REGN executives highlighted continued growth across key marketed products, a broad late-stage pipeline and an ongoing focus on science-driven business development during a discussion with Bernstein analyst Jeffrey Walch.
Regeneron Highlights Dupixent Growth, Cemdisiran Catalysts and EYLEA HD Momentum
Regeneron Pharmaceuticals NASDAQ: REGN outlined growth opportunities for Dupixent, pipeline catalysts for cemdisiran and continued commercial momentum for EYLEA HD during the Morgan Stanley Global Healthcare Conference.
Regeneron Pharmaceuticals, Inc. (REGN) Presents at Morgan Stanley 24th Annual Global Healthcare Conference Transcript
Regeneron Pharmaceuticals, Inc. (REGN) Presents at Morgan Stanley 24th Annual Global Healthcare Conference Transcript
Regeneron Eyes 2026 Catalysts as EYLEA HD and DUPIXENT Drive Growth
Regeneron Pharmaceuticals NASDAQ: REGN executives outlined plans for continued growth across its commercial portfolio, upcoming regulatory milestones and pipeline programs during a Wells Fargo investor conference appearance.
Regeneron Pharmaceuticals, Inc. (REGN) Presents at Wells Fargo 21st Annual Healthcare Conference Transcript
Regeneron Pharmaceuticals, Inc. (REGN) Presents at Wells Fargo 21st Annual Healthcare Conference Transcript
Regeneron: Why I Still See Upside After The Rally
Regeneron Pharmaceuticals ends August on a high note. The decline in U.S. sales of Eylea following the launch of biosimilars is no longer putting pressure on REGN stock. That's because REGN's Dupixent sales reached €5.15 billion in the second quarter, up 23.6% sequentially.
REGN Soars 21.9% in a Month: Buy, Sell or Hold the Stock?
Regeneron's Eylea HD and Dupixent strength are fueling growth, while oncology gains and pipeline progress support its outlook.
